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Abstract
Nestin-Cre mice express Cre recombinase under control of the rat nestin promoter and central nervous system (CNS)
enhancer. While endogenous Nestin is expressed in some other tissues including the pituitary gland, Nestin-Cre mice induce
recombination predominantly in the CNS. For this reason, they have been widely used to explore gene function or cell fate
in the latter. Pituitary hormonal deficiencies, or hypopituitarism, are associated with a wide range of symptoms and with a
significant morbidity. These can have a neural and/or a pituitary origin as the gland’s secretions are controlled by the
hypothalamus. We report here that Nestin-Cre mice themselves are affected by mild hypopituitarism. Hence, physiological
consequences are expected, especially in combination with defects resulting from Cre mediated deletion of any gene under
investigation. To further investigate the origin of this phenotype, we re-examined the activity of the transgene. We
compared it with expression of Nestin itself in the context of the hypothalamo-pituitary axis, especially in the light of a
recent report showing pituitary Nestin-Cre activity, which contrasts with previous data. Our results disagree with those of
this recent study and do not support the claim that Nestin positive cells are present in the pituitary anlagen, the Rathke’s
pouch (RP). Moreover we did not observe any significant activity in the post-natal pituitary, in agreement with the initial
report.
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Introduction
Disorders affecting the hypothalamo-pituitary axis can result in
single or multiple hormonal deficiencies, or hypopituitarism. They
are associated with a wide range of symptoms, reflecting the roles
of the different pituitary hormones, and with a significant
morbidity. They can result from pituitary or/and central nervous
system (CNS) defects as the gland’s secretions are under
hypothalamic control. Isolated Growth Hormone Deficiency
(IGHD) is prevalent, with an incidence of 1 in 4000–10000 live
births [1]. Some of these disorders have been shown to stem from
abnormal development of the hypothalamo-pituitary axis, and
several genes responsible for these defects have been characterized.
However, because of the intricate interactions between both
components of the axis, the hypothalamus within the CNS and the
pituitary gland, which mostly originates from oral ectoderm, and
also the complex expression pattern of some of the genes whose
deletion or mutation results in hypopituitarism, it has sometimes
been difficult to pinpoint the origin of defects ultimately affecting
post-natal pituitary secretions (for review see [2]).
In order to investigate complex phenotypes, conditional deletion
of a gene of interest is often required. To achieve this goal the Cre-
Lox system has been widely used. The Cre enzyme from the
bacteriophage P1 catalyzes DNA recombination between LoxP
sites allowing, in particular, deletion of the intervening DNA
fragment [3]. Deletion can be controlled both in time and space by
using a tissue specific promoter to drive Cre expression. Nestin-
Cre mice, expressing Cre recombinase under control of the rat
nestin promoter and its CNS specific enhancer, were initially
generated to specifically inactivate the glucocorticoid receptor (Gr)
gene in the nervous system [4]. Indeed, while endogenous Nestin is
expressed in the post-natal pituitary [5], the CNS specific
transgene does not delete Gr in the gland [4]. Since then,
Nestin-Cre mice have been widely used to investigate gene
function or cell fate in the CNS. In the context of the
hypothalamo-pituitary axis, they provide a useful tool in order
to distinguish whether a phenotype originates from a pituitary or a
hypothalamic defect, when the protein of interest is expressed in
both tissues, during embryonic development and/or in the adult.
In recent years however, Cre activity or transgene insertion, have
sometimes been associated with side effects. We report here that
Nestin-Cre mice are themselves affected by hypopituitarism and
this is expected to have physiological consequences.
Moreover, in contrast with the initial study reporting Nestin-Cre
generation [4], Nestin-Cre activity was recently reported in the
pituitary [6]. Cell lineage analysis using this transgene, and an
inducible version of it (Nestin-Cre-ER), suggested that Nestin
positive cells represent adult stem cells. As this would have
implications for using Nestin-Cre in the context of the hypotha-
lamo-pituitary axis to distinguish a pituitary from a CNS
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characterized Nestin-Cre activity and Nestin expression itself in
the context of the hypothalamo-pituitary axis both in the embryo
and in the adult. Our results differ from those of Gleiberman et al.
and do not support the claim that Nestin positive cells are present
in the early embryonic pituitary. Moreover we, and others [4,7],
do not detect any significant activity of this transgene in the adult
pituitary.
Results
Nestin-Cre mice display mild hypopituitarism
Anterior pituitary hormone contents were measured by radio-
immunoassay (RIA) just before birth (18.5dpc), when pituitary
hormones are present but their secretion is not yet under
hypothalamic control, and in 2 month-old adults, comparing
heterozygous Nestin-Cre and controls (littermates or wild-type
animals from the same genetic background). Before birth, Growth
Hormone (GH) contents are similar in both groups (Figure 1A).
However, in adult, Nestin-Cre mice display a 70% to 80%
reduction in GH, prolactin (PRL) and thyroid stimulating
hormone (TSH) contents while luteinizing hormone (LH) and
adrenocorticotropic hormone (ACTH) levels are not affected
(Figure 1A). We obtained the same results in males and females
(data not shown). To exclude the possibility that our colony is
affected by an additional mutation leading to the phenotype, we
confirmed these results on animals bred in another colony (data
not shown). In contrast, mice homozygous for b-actin-Cre [8],
which express Cre ubiquitously, were not affected by hypopitu-
itarism (data not shown). This implies either that relative levels of
Cre activity are critical or that the Nestin-Cre transgene has
compromised the activity of a gene at its integration site. Rather
than a defect within the pituitary itself, the phenotype is more
consistent with compromised hypothalamic development or
function because the deficits only start post-natally, when the
secretions are under CNS control. Moreover, deficiencies are
Figure 1. Anterior pituitary contents and hypothalamus morphology. (A)Graphic representation of anterior pituitary hormonal contents
measured by RIA of 18.5dpc and 2 month-old wild-type and Nestin-Cre samples (five samples/genotype were examined). Hormonal contents
correspond to 10
28 g/pituitary for GH at 18.5dpc (values: WT: 15.28 SEM62.2 Nestin-Cre: 17.1 SEM62.4) and 10
26 g/pituitary for GH (values: WT:
103.3 SEM66.94 Nestin-Cre: 24.37 SEM62.34), 10
27 for PRL (values: WT: 26.67 SEM64.49 Nestin-Cre: 5.57 SEM60.76) and LH (values: WT: 17.5
SEM60.98 Nestin-Cre: 21 SEM62.86) and 10
28 for TSH (values: WT: 63.9 SEM64.93 Nestin-Cre: 32.57 SEM61.19) and ACTH (values: WT: 23.73
SEM61.82 Nestin Cre: 20.24 SEM62.91) in 2 month-old animals; ***p,0.001; NS: not significant. (B) Hematoxylin and eosin stained transverse
sections through the hypothalamus of 2 month-old wild-type and Nestin-Cre males. ME: Median eminence; Arc: Arcuate nucleus; DM: Dorsomedial
hypothalamic nucleus.
doi:10.1371/journal.pone.0011443.g001
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and TSH, which belong to the same lineage defined by expression
of the transcription factor Pit-1. This factor is expressed before
differentiation of these endocrine cells in the embryo and is
required for their post-natal expansion (for review see [2]). This
suggests that the hypothalamic input on Pit-1 positive cells to
control hormonal secretion, synthesis or cell proliferation, is
affected in these mice. Histological examination of different
hypothalamic nuclei (arcuate, dorso and ventro-medial, paraven-
tricular, medial and supra-mammilary) in Nestin-Cre animals did
not however reveal any gross morphological defect (Figure 1B).
The Nestin-Cre transgene does not show any significant
activity in the pituitary gland
In the context of the hypothalamo-pituitary axis, Nestin itself is
known to be expressed in embryonic and adult neural stem/
progenitor cells. In the post-natal gland, Nestin is found in
different types of non-endocrine cells [5]. A subset of Nestin
+ve
cells comprise folliculo-stellate (FS) cells, a heterogenous popula-
tion whose function is unclear. Nestin is also present in the
periluminal cell layer, which is proposed to contain progenitors.
Finally other Nestin
+ve cells are part of the gland’s connective
tissue [5]. In contrast, Nestin-Cre expression was initially reported
to be CNS specific [4]. However, a recent report challenged this
observation by showing that a Nestin-GFP transgene generated
using similar regulatory elements to that of the original Nestin-Cre
transgene is expressed in the pituitary anlagen or Rathke’s pouch
(RP) [6]. Moreover Nestin-Cre and an inducible Nestin-Cre-ER
version were shown to generate significant staining in the adult
gland, in cell lineage tracing experiments [6]. This had not been
reported previously. To investigate this further, we re-evaluated
the recombination pattern given by Nestin-Cre in the context of
hypothalamo-pituitary axis development, by making use of the
Rosa26reporterEYFP allele. This gives EYFP expression in cells in
which the transgene is active and in all their descendants. We
compared this pattern with endogenous Nestin expression.
In the embryo (13.5dpc), Nestin co-localizes with EYFP in the
ventral diencephalon (VD), but both are absent from the
infundibulum, a specific domain within the VD that gives rise to
the pituitary stalk and posterior lobe of the gland, and also from
the RP (Figure 2A,B). In fact, we did not detect any pituitary
Nestin expression or Nestin-Cre activity up to 16.5dpc, although
at 18.5dpc Nestin protein was present in the developing gland
(Figure 2C,D and data not shown). This is in agreement with the
results of Imai et al. who found lack of recombination in the
developing pituitary at 15.5dpc with a Nestin-Cre strain
independently generated with the rat Nestin promoter and CNS
enhancer [9]. Therefore, in the embryo, until at least 16.5dpc,
Nestin-Cre and Nestin itself display the same pattern in the
context of the developing hypothalamo-pituitary axis, both being
absent from the embryonic pituitary. This is in contrast with the
observation of Gleiberman’s et al. showing Nestin-GFP expression
in RP [6].
Post-natally, Nestin and EYFP are both expressed in the adult
posterior pituitary, which is of neural origin (Figure 2E, F).
However, very few EYFP
+ve cells result from Nestin-Cre activity in
the adult anterior pituitary (Figure 2E, EYFP
+ve cells represent
0.7% of anterior lobe cells in this 11 month-old specimen; 8547
Figure 2. Nestin-Cre activity and Nestin expression. (A, B) Immunofluorescence for GFP and Nestin in 13.5dpc NestinCre; R26RYFP embryo.
Ventral diencephalon (VD) (A) and Ratkhe’s pouch (RP) (B). Note that EYFP expression always correlates with that of Nestin within the CNS. (C, D)
Immunofluorescence for Nestin on 16.5dpc (C) and 18.5dpc (D) wild-type pituitaries. (E, F) Immunofluorescence for GFP (E) and for GFP and Nestin (F)
on Nestin-Cre; R26ReporterEYFP eleven month-old pituitaries. The arrows point to Nestin
+ve, EYFP
+ve cells. Scale bar: 50 mm; ant.: anterior; int.:
intermediate; pos.: posterior; inf: infundibulum.
doi:10.1371/journal.pone.0011443.g002
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+ve nuclei were counted). Moreover, these are also Nestin
+ve
and therefore represent only a minute fraction of the Nestin
+ve
population (in contrast, the Rosa26reporterEYFP allele recom-
bined ubiquitously in the pituitary gland when bred to b-actin-
Cre; data not shown). This result agrees with the initial study
describing Nestin-Cre mice [4] and also with a more recent study,
using the same strain and describing Cre reporter expression in the
posterior lobe but not in the anterior pituitary [7]. However, these
results conflict with the Nestin-GFP transgene expression observed
in the adult in Gleiberman’s et al. This discrepancy may reflect the
use of not quite identical (although they are very similar)
regulatory elements or different integration sites of the transgenes.
Moreover, our results also contrast with the lineage tracing data of
Gleiberman et al. where, using the same Nestin-Cre, GFP reporter
expression was found in many pituitary cells (up to 20% of the
anterior lobe in 5 month-old animals) including endocrine cells. It
should be noted that different reporter mice were used in this study
[10] and in Gleiberman et al. [11]. While in both cases the same
locus (Rosa26) was targeted, the constructs are slightly different.
Discussion
Nestin-Cre mice are widely used to dissect gene and cell
function in the CNS. We report here that these mice are affected
by mild hypopituitarism and this is expected to have physiological
consequences, especially in combination with any defects resulting
from loss of the gene under investigation. The use of Nestin-Cre
control samples is therefore necessary to distinguish real
consequences of deletion of the gene under investigation from
side effects resulting from Nestin-Cre associated hypopituitarism.
In the context of the hypothalamo-pituitary axis, their specific
CNS activity was recently challenged by a study reporting activity
of this, and another similar transgene (Nestin-GFP) both in the
embryonic and adult pituitary [6]. Based on cell lineage analysis,
this report suggested that Nestin positive cells represent adult
pituitary stem cells. In contrast, we, and others, did not detect any
Nestin expression or Nestin-Cre activity [9] until at least 16.5dpc.
In the adult, very few cells showed transgene activity, in agreement
with previous studies [4,7]. Therefore our data do not support the
claim that Nestin positive cells are present in the early pituitary
and cell lineage analysis using Nestin-Cre did not generate any
significant labelling in the post-natal anterior pituitary.
Nestin-Cre mice and hypopituitarism
There have now been several reports of side effects and pitfalls
associated with Cre activity or transgene insertion. These include
apoptosis and anaemia in embryonic development, impairment of
pancreatic function (glucose intolerance), microcephaly and
hydrocephaly, and chromosome rearrangements in spermatids
[12,13,14,15]. The mammalian genome contains cryptic or
‘‘pseudo-LoxP’’ sites that can be used as functional recognition
sites for the enzyme [16,17]. It has therefore been hypothesized
that high expression or long exposure to Cre activity might trigger
recombination leading to chromosomal rearrangements in mam-
malian cells in vivo. Transgene integration site might also affect
activity of surrounding genes, leading to defects. Here, we have not
analyzed the origin of the hormonal deficiencies. However, b-
actin-Cre animals, that express Cre ubiquitously [8], were not
affected by hypopituitarism suggesting that either relative levels of
Cre activity are critical or that the site of insertion of the transgene
might be responsible for the defect in Nestin-Cre mice.
The hypopituitarism displayed by Nestin-Cre mice is post-natal
and specific to the Pit-1 lineage (GH, PRL and TSH cells). As we
have shown here that the transgene is active in the CNS but not in
the embryonic pituitary and at very low level in the adult gland, a
defect within these endocrine cells, or affecting their emergence in
the embryo is very unlikely to be at the origin of the phenotype.
The embryonic VD is important early on for RP morphogenesis
and maintenance and Nestin-Cre is active in this tissue. However,
later on, as pituitary endocrine cells differentiate, VD does not
seem to have a significant effect on the developing gland. Indeed,
up to now, mutations affecting VD therefore hypothalamus
development (Gsh-1 mutants [18]) or function (little mouse, GFR
receptor mutants [19]) have only been shown to affect the post-natal
pituitary whose morphogenesis was normal. In Nestin-Cre mice, it
is therefore rather the post-natal hypothalamus, controlling the
gland’s secretions, that is likely to be responsible for the
hypopituitarism. The hypothalamus modulates hormonal secre-
tion, synthesis and endocrine cell proliferation. Any of these inputs
directed specifically to the endocrine cells of the Pit-1 lineage could
be affected in the Nestin-Cre mice inducing as a consequence a
reduction in pituitary hormonal contents. Non-specific Cre activity
within these regulatory cells or integration of the transgene in a site
important for their differentiation or function may underline the
defect. This defect is expected to be rather subtle, as histological
examination of the hypothalamus did not reveal any gross
morphological abnormality.
Finally, the hypopituitarism displayed by Nestin-Cre mice has
implications for using them to study pituitary phenotypes. Where
Nestin-Cre is used, pituitary contents in conditional mutants must
be compared with that of Nestin-Cre animals without the floxed
gene as controls. More generally, mild hypopituitarism would be
compensated for in young animals by increasing hypothalamic
input, but, as compensation eventually fails in the adult,
deficiencies would slowly develop with potential physiological
consequences (e.g. IGF1 deficiency, I.C. Robinson, personal
communication). In particular it has been shown that adult onset
GH and IGF-1 deficiencies affect neurogenesis [20]. These effects
would arise in combination with any defects resulting from loss of
the gene under study.
The Nestin-Cre transgene is not significantly active in the
pituitary
Nestin expression in the pituitary had only been described post-
natally to our knowledge. It is present in different non-endocrine
cells [5], in a subset of FS cells whose function remains unclear, in
potential progenitors located in the epithelium flanking the
pituitary cleft and in supporting cells (for review see, [21]).
Recently, we have shown that spheres obtained from adult
pituitaries [22] express SOX2, can proliferate and also differen-
tiate, suggesting that SOX2 positive cells may represent adult
pituitary progenitor/stem cells [23]. In the spheres, Nestin
expression was initiated after SOX2 suggesting that Nestin
positive cells may represent more determined cells, corresponding
to transit amplifying progenitors. Therefore, there is clearly a link
between Nestin expression and adult progenitor/stem cells in the
pituitary.
We first analysed Nestin expression in the embryo and did not
see any expression before 18.5 dpc. In parallel, we, and others [9],
did not detect any Nestin-Cre activity until at least 16.5dpc. In
contrast, Gleiberman et al. report expression of a Nestin-GFP
transgene in RP at 11.5dpc. This discrepancy may reflect use of
slightly different promoter/enhancer elements, as Gleiberman et
al. derived their Nestin-GFP transgene independently, although
from similar sequences, or it might reflect different integration
sites. However, if Nestin itself is not expressed in RP, the transgene
activity is not reflecting expression of the protein at this stage and
location and is therefore likely to be ectopic.
Nestin-Cre and Hypopituitarism
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Cre activity represents only a minute fraction of Nestin-positive
cells (0.7% of total anterior lobe cells), in agreement with others
[4,7]. This is also consistent with a lack of significant activity of the
transgene in the embryo. However, these results conflict with the
lineage tracing data of Gleiberman et al., where GFP reporter
expression is found in many pituitary cells (up to 20% of the
anterior lobe) including endocrine cells. The fact that these
differentiated endocrine cells are GFP
+ve prompted these authors
to suggest that the hormone negative, Nestin
+ve, and by extension
Nestin-Cre
+ve cells represent progenitors. In our hands, the few
EYFP
+ve cells we have found in the adult are unlikely to represent
progenitors as they always co-expressed Nestin. They may
therefore belong to another sub-population of Nestin
+ve cells.
The discrepancy observed in activity of the transgene in the
pituitary is difficult to explain as the mice used here, elsewhere [7]
and in Gleiberman’s study have the same origin ([4], The Jacskon
laboratory). As described above, the reporter mice used here and
in Gleiberman et al. are not identical. They both result from a
targeted insertion in the Rosa26 locus but the constructs are
slightly different. However, in a study where the two reporter lines
were compared, it was concluded that the one we used is the most
efficient, so this does not provide an explanation for the
discrepancy [24]. Moreover, expression of the Gr gene was intact
in the gland in the initial study [4] and, using a Rosa26LacZ
reporter, Wettschureck et al. also failed to observe any anterior
pituitary expression [7]. As we discussed above, at least some
Nestin positive cells are most probably adult pituitary progenitors.
Therefore the transgene used in Gleiberman et al. could display
genuine expression in the adult, reflecting Nestin expression.
However ectopic activity in the embryonic gland such as the one
observed with the Nestin-GFP transgene in RP progenitors at
11.5dpc [7] would give rise to significant staining of endocrine cells
post-natally, as anterior pituitary cells derive from RP (for review
see [2]). To identify Nestin positive cells as stem cells would require
showing exclusive co-localization of Cre and Nestin.
In conclusion, our work highlights the importance of carrying
out controls both to relate the activity of an enhancer driving Cre
transgene expression to that of the endogenous gene, and to reveal
whether the Cre transgene leads to a relevant phenotype by itself.
Materials and Methods
Ethics Statement
All experiments carried out on mice were approved under the
UK Animal (scientific procedures) Act (Project licence 80/1949).
Mice
We maintain Nestin-Cre [4] and b-actin-Cre mice on an MF1
background (random bred, NIMR). Nestin-Cre mice were
purchased from the Jackson Laboratory (Origin, R. Klein,
EMBL). R26REYPF mice were obtained from S. Srinivas [10].
Embryos were obtained by mating homozygous Rosa26reporter-
EYFP females to heterozygous Nestin-Cre males. The day of
vaginal plug corresponds to 0.5dpc. For RIA, we analyzed
heterozygous Nestin-Cre animals and homozygous b-actin-Cre
mice. Age-matched MF1 mice and Cre-negative siblings were used
as controls. Nestin-Cre mice (Origin, R. Klein, EMBL) maintained
on C57BL6 background were obtained from the London Research
Institute (LRI, CRUK) and used as an independent colony to
confirm the hypopituitarism phenotype.
Immunofluorescence and histology
For frozen sections, embryos were fixed in 4% paraformalde-
hyde for 1 h at 4uC, while adults were perfused intracardially with
4% paraformaldehyde. Samples were then cryoprotected in 30%
sucrose and embedded in OCT (BDH). Immunufluorescence was
performed on 12 mm sections using a 1:500 dilution of a rabbit
antibody to GFP (recognizing EYFP – Chemicon) and a 1:100
dilution of a mouse antibody to Nestin (DSHB, USA). Detection
was performed by using a 1:500 dilution of anti-rabbit and anti-
mouse antibodies conjugated to Alexa-488 and Alexa-555
respectively (Molecular Probes). For histology, 2 month-old brains
were fixed in Bouin’s solution overnight, dehydrated and
embedded in paraffin. Samples were then sectioned and stained
with hematoxylin and eosin.
Radioimmunoassay
Pituitaries were homogenised in phosphate-buffer saline and
assayed for anterior pituitary hormones using National Hormone
and Pituitary Program reagents kindly provided by A.L. Parlow, as
described in [25].
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